Meeting of the Presidential Advisory Council on HIV/AIDS, 58745-58746 [2024-15964]
Download as PDF
58745
Federal Register / Vol. 89, No. 139 / Friday, July 19, 2024 / Notices
satisfaction with the activity. The
RWHAP Regional AETC Program
recipients will gather data on the
training activities they conduct using
six data collection instruments. The
Individual Participant Record is
completed at least once every reporting
period by participants actively engaging
in Regional AETC activities. This form
includes Regional AETC participant
demographic, workplace, and clientserved data for the participant’s
respective provider sites. The Training
Activity Record is a form completed at
the end of each Regional AETC activity
that takes place during the reporting
period and is completed by the regional
recipients. This form describes the
activity in hours, modality, and topic(s).
The PT Site Characteristics/Outcomes
form collects site characteristics
information for PT recipient sites only,
like clinic activities and procedures,
and aggregate counts of clients. PT sites
provide clinical services and differ from
IPE sites that support students, thus
necessitating a different form. The IPE
Site Characteristics/Outcomes form
collects site characteristics information
for IPE recipient sites only. The
Participant Post-Activity Immediate
Survey collects information from
participants immediately after an
activity, specifically, their satisfaction
and potential increased knowledge due
to participating in said activity. The IPE
Long-Term form collects 1-year postparticipation information from
participant students who engaged in an
IPE program to gauge involvement in
the field of HIV care and treatment.
Need and Proposed Use of the
Information: HRSA uses the data
collected when conducting RWHAP
AETC programmatic assessments to
determine future program needs. These
data allow HRSA to identify where gaps
exist in training HIV professionals as
well as to measure whether training
activities are meeting the goals of the
National HIV/AIDS Strategy and the
RWHAP statute.
Likely Respondents: RWHAP Regional
AETC participants complete the
Individual Participant Record at least
once a reporting period. Regional AETC
recipients complete a Training Activity
Record for each training activity they
conduct during the reporting period. All
Regional AETC participants will take
the Participant Post-Activity Survey
immediately after any attended activity.
The IPE Long-Term form will only be
completed by participants who engaged
in an IPE program, 1-year postparticipation in the IPE program.
Finally, PT recipients will complete the
PT Site Characteristics/Outcomes form
at least once per reporting period, and
IPE recipients will complete the IPE Site
Characteristics/Outcomes form at least
once per reporting period.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Individual Participant Record ................................................................................
Training Activity Record ........................................................................................
PT, Site Characteristics and Outcomes ................................................................
IPE, Site Characteristics and Outcomes ..............................................................
Participant Post-Activity Immediate Survey ..........................................................
IPE, Long-Term .....................................................................................................
Combined Data Set ...............................................................................................
59,576
12,226
128
86
59,576
4,403
8
1
1
1
1
3
1
1
59,576
12,226
128
86
178,728
4,403
8
0.27
0.21
0.31
0.09
0.06
0.07
64
16,085.52
2,567.46
39.68
7.74
10,723.68
308.21
512.00
Total ...............................................................................................................
136,003
........................
255,155
........................
30,244.29
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
responses per
respondent
Number of
respondents
Form name
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024–15957 Filed 7–18–24; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
18:53 Jul 18, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on HIV/AIDS
Office of the Secretary, Office
of the Assistant Secretary for Health,
Department of Health and Human
Services.
AGENCY:
ACTION:
Notice of a virtual meeting.
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Service is hereby giving notice that the
Presidential Advisory Council on HIV/
AIDS (PACHA or the Council) will
convene the 82nd full council meeting
on Wednesday, August 28–Thursday,
August 29, 2024. The meeting will
include panels on the U.S. government’s
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
global HIV response; the science and
impact of ‘‘Undetectable =
Untransmittable’’, or U = U; Affordable
Care Act risk adjustment model to
expand access and uptake of PrEP. It
will be open to the public and there will
be a public comment session during the
meeting; pre-registration is required to
provide public comment. To pre-register
to provide public comment, please send
an email to PACHA@hhs.gov and
include your name, organization, and
title by close of business Wednesday,
August 21, 2024. If you decide you
would like to provide public comment
but do not pre-register, you may submit
your written statement by emailing
PACHA@hhs.gov by close of business
Thursday, September 5, 2024. The
meeting agenda will be posted on the
PACHA page on HIV.gov at https://
E:\FR\FM\19JYN1.SGM
19JYN1
58746
Federal Register / Vol. 89, No. 139 / Friday, July 19, 2024 / Notices
www.hiv.gov/federal-response/pacha/
about-pacha prior to the meeting.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The meeting will convene on
Wednesday, August 28, 2024 from
approximately 1 p.m. to 5:30 p.m. (ET)
and Thursday, August 29, 2024 from
approximately 1 p.m. to 5:30 p.m. (ET).
National Institutes of Health
This meeting will be held
virtually. To stream the meeting, please
visit www.hhs.gov/live.
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Arthritis and
Musculoskeletal and Skin Diseases
Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov/).
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DATES:
ADDRESSES:
Ms.
Chloe Loving, MPH, Committee
Manager for PACHA, at PACHA@
hhs.gov or 202–795–7697. Additional
information can be obtained by
accessing the Council’s page on the
HIV.gov site at www.hiv.gov/pacha.
FOR FURTHER INFORMATION CONTACT:
PACHA
was established by Executive Order
12963, dated June 14, 1995, as amended
by Executive Order 13009, dated June
14, 1996 and is currently operating
under the authority given in Executive
Order 14109, dated September 29, 2023.
The Council was established to provide
advice, information, and
recommendations to the Secretary
regarding programs and policies
intended to promote effective HIV
diagnosis, treatment, prevention, and
quality care services. The functions of
the Council are solely advisory in
nature. The Council consists of not more
than 35 members. Council members are
selected from prominent community
leaders with particular expertise in, or
knowledge of, matters concerning HIV
and AIDS, public health, global health,
population health, philanthropy,
marketing or business, as well as other
national leaders held in high esteem
from other sectors of society. PACHA
selections also include persons with
lived HIV experience and persons
disproportionately affected by HIV.
Council members are appointed by the
Secretary.
SUPPLEMENTARY INFORMATION:
ddrumheller on DSK120RN23PROD with NOTICES1
Dated: July 9, 2024.
Caroline Talev,
Executive Director, Presidential Advisory
Council on HIV/AIDS, Senior Management
Analyst, Office of Infectious Disease and HIV/
AIDS Policy, Office of the Assistant Secretary
for Health, Department of Health and Human
Services.
[FR Doc. 2024–15964 Filed 7–18–24; 8:45 am]
BILLING CODE 4150–43–P
VerDate Sep<11>2014
18:53 Jul 18, 2024
Jkt 262001
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Meeting
Name of Committee: National Arthritis and
Musculoskeletal and Skin Diseases Advisory
Council.
Date: September 17, 2024.
Open: 9:30 a.m. to 2:45 p.m.
Agenda: Discussion of Program Policies
and Issues.
Place: National Institutes of Health,
Building 31, 31 Center Street, Bethesda, MD
20892 (Hybrid Meeting).
Closed: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Building 31, 31 Center Street, Bethesda, MD
20892 (Hybrid Meeting).
Contact Person: Darren D. Sledjeski, Ph.D.,
Director, Division of Extramural Activities
(DEA), National Institute of Arthritis and
Musculoskeletal and Skin Diseases, 6701
Democracy Blvd., Bethesda, MD 20892, (301)
451–7766, darren.sledjeski@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
procedures at https://www.nih.gov/about-
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
nih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.niams.nih.gov/about/working-groups/
advisory-council, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: July 16, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–15950 Filed 7–18–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Interventional Agents
Chemistry Services (IACS) Services.
Date: August 5–12, 2024.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70A,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Soheyla Saadi, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
E:\FR\FM\19JYN1.SGM
19JYN1
Agencies
[Federal Register Volume 89, Number 139 (Friday, July 19, 2024)]
[Notices]
[Pages 58745-58746]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15964]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Presidential Advisory Council on HIV/AIDS
AGENCY: Office of the Secretary, Office of the Assistant Secretary for
Health, Department of Health and Human Services.
ACTION: Notice of a virtual meeting.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Service is hereby giving notice that the
Presidential Advisory Council on HIV/AIDS (PACHA or the Council) will
convene the 82nd full council meeting on Wednesday, August 28-Thursday,
August 29, 2024. The meeting will include panels on the U.S.
government's global HIV response; the science and impact of
``Undetectable = Untransmittable'', or U = U; Affordable Care Act risk
adjustment model to expand access and uptake of PrEP. It will be open
to the public and there will be a public comment session during the
meeting; pre-registration is required to provide public comment. To
pre-register to provide public comment, please send an email to
[email protected] and include your name, organization, and title by close
of business Wednesday, August 21, 2024. If you decide you would like to
provide public comment but do not pre-register, you may submit your
written statement by emailing [email protected] by close of business
Thursday, September 5, 2024. The meeting agenda will be posted on the
PACHA page on HIV.gov at https://
[[Page 58746]]
www.hiv.gov/federal-response/pacha/about-pacha prior to the meeting.
DATES: The meeting will convene on Wednesday, August 28, 2024 from
approximately 1 p.m. to 5:30 p.m. (ET) and Thursday, August 29, 2024
from approximately 1 p.m. to 5:30 p.m. (ET).
ADDRESSES: This meeting will be held virtually. To stream the meeting,
please visit www.hhs.gov/live.
FOR FURTHER INFORMATION CONTACT: Ms. Chloe Loving, MPH, Committee
Manager for PACHA, at [email protected] or 202-795-7697. Additional
information can be obtained by accessing the Council's page on the
HIV.gov site at www.hiv.gov/pacha.
SUPPLEMENTARY INFORMATION: PACHA was established by Executive Order
12963, dated June 14, 1995, as amended by Executive Order 13009, dated
June 14, 1996 and is currently operating under the authority given in
Executive Order 14109, dated September 29, 2023. The Council was
established to provide advice, information, and recommendations to the
Secretary regarding programs and policies intended to promote effective
HIV diagnosis, treatment, prevention, and quality care services. The
functions of the Council are solely advisory in nature. The Council
consists of not more than 35 members. Council members are selected from
prominent community leaders with particular expertise in, or knowledge
of, matters concerning HIV and AIDS, public health, global health,
population health, philanthropy, marketing or business, as well as
other national leaders held in high esteem from other sectors of
society. PACHA selections also include persons with lived HIV
experience and persons disproportionately affected by HIV. Council
members are appointed by the Secretary.
Dated: July 9, 2024.
Caroline Talev,
Executive Director, Presidential Advisory Council on HIV/AIDS, Senior
Management Analyst, Office of Infectious Disease and HIV/AIDS Policy,
Office of the Assistant Secretary for Health, Department of Health and
Human Services.
[FR Doc. 2024-15964 Filed 7-18-24; 8:45 am]
BILLING CODE 4150-43-P